Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders. Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain. By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS). The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.
Looking for a particular Carthera employee's phone or email?
The Carthera annual revenue was $782000 in 2026.
Frédéric Sottilini is the CEO of Carthera.
22 people are employed at Carthera.
Carthera is based in Lyon, Auvergne-Rhône-Alpes.
The NAICS codes for Carthera are [541713, 5417, 54171, 541, 54].
The SIC codes for Carthera are [873, 87].